Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study
Relapsing-remitting multiple sclerosis (RRMS) is a degenerative, inflammatory disease of the central nervous system in which symptoms and disability progression vary significantly among patients. Teri-REAL was a prospective, real-world observational study that examined quality-of-life (QoL) and trea...
Main Authors: | Krisztina Bencsik, Enikő Dobos, Zita Jobbágy, Adrienne Jóri Birkás, Krisztina Kovács, Mária Sátori, Gyula Lencsés, Gabor Bartok, Erika Losonczi, László Vécsei, on behalf of the Teri-REAL Investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/5/598 |
Similar Items
-
TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW)
by: E. V. POPOVA, et al.
Published: (2016-12-01) -
Lichenoid drug eruption induced by teriflunomide
by: Fatima-Zahra Agharbi, et al.
Published: (2023-01-01) -
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
by: José E. Meca-Lallana, et al.
Published: (2023-10-01) -
Teriflunomide as a therapeutic means for myelin repair
by: Peter Göttle, et al.
Published: (2023-01-01) -
Antidepressant effect of teriflunomide via oligodendrocyte protection in a mouse model
by: Shuting Luo, et al.
Published: (2024-04-01)